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Abstract
Etomidate is a potent suppressant of adrenal steroidogenesis,
effectively inducing reversible pharmacological adrenalectomy.
Recent evidence suggests that for every five patients with septic
shock given etomidate without corticosteroid supplementation, one
patient will die as a consequence. Other critically ill patients are
also at possible risk, and this risk requires further exploration.
Etomidate will also confound investigations into the effects of
disease states on adrenal function, and should therefore be
avoided. A moratorium on the use of etomidate in critically ill
patients outside clinical trials may be prudent until its safety is
established.
Etomidate is a hypnotic with a sixfold better therapeutic index
than alternatives such as thiopental or propofol, making it an
agent of choice for induction of anaesthesia in critically ill,
haemodynamically unstable patients [1,2]. This together with
its favourable pharmacokinetic profile also led to its use by
infusion for sedation of ventilated patients in intensive care
units (ICUs). This practice was largely abandoned more than
20 years ago as a result of etomidate’s association with
increased mortality, which was attributed to profound
suppression of adrenal steroidogenesis primarily through its
potent inhibition of the enzyme 11β-hydroxylase [3-5]. In
contrast, single-bolus administration of etomidate has been
considered safe by most commentators [6], but not all [7],
and its niche use by many specialities has continued [2].
The risk–benefit profile of etomidate bolus administration has
been brought into focus again by recent studies. In the
present issue of Critical Care Mohammad and colleagues
report results of a retrospective review of adrenal function in
patients with septic shock, comparing patients who did
receive and who did not receive etomidate [1]. The
prevalence of a blunted response to cosyntropin was 50%
greater in those patients who received etomidate, although
the excess mortality was not statistically significant. The study
size and design preclude inferences on mortality.
The results of Mohammad and colleagues add to a
prospective observational study of critically ill, mechanically
ventilated patients that found a single bolus of etomidate
given 24 hours before a standard cosyntropin test to be the
most important predictor of relative adrenal insufficiency –
and overall nonresponders to cosyntropin had a significantly
higher mortality [8]. Further evidence comes from an
observational study of 60 children with meningococcal
sepsis, none of whom received corticosteroid supplemen-
tation [9]. Adrenal dysfunction demonstrated by extremely
high adrenocorticotrophin concentrations and low total
cortisol concentrations were associated with increased IL-6
concentrations and use of etomidate. Seven of the eight
patient deaths reported received etomidate.
While all of these studies confirm that etomidate is
associated with adrenal insufficiency, they were not designed
to answer whether this effect was detrimental. In this context,
Annane has provided important data that strongly suggest
that etomidate administration, if unsupplemented with cortico-
steroids, in patients with septic shock results in excess
mortality [10]. In a reanalysis of a double-blind clinical trial of
299 patients with septic shock randomised to receive
placebo or corticosteroids, 77 (26%) patients received
etomidate [10,11]. Ninety-four per cent of these etomidate-
treated patients were nonresponders to cosyntropin, and the
blockade of steroidogenesis lasted around 72 hours. Fluid
and vasopressor requirements were greater compared with
those patients intubated with alternative methods. The key
finding was the difference in mortality between those
etomidate-treated patients randomised to placebo (76%) and
those randomised to corticosteroids (55%). This statistically
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significant absolute risk reduction (survival advantage) of
21% of those given corticosteroids translates into a number
needed to treat of five patients. The early advantage of
relative haemodynamic stability at intubation, which itself is
not an important patient-centred outcome and can be
managed in a critical care environment, seems trivial in this
context.
Although it might be argued that steroid supplementation
would obviate these important adverse consequences, there
are problems with this approach in clinical practice. Firstly
there is the problem of identifying which patients are at risk.
Although the cumulative data for patients with septic shock
are strong, not all of these patients are treated with cortico-
steroids [9]. Other critically ill patients without septic shock
may also be at risk but the data are observational and weaker
[8]. There can be a lag time between the onset of iatrogenic
adrenal insufficiency, its recognition and corticosteroid supple-
mentation, particularly if intubation occurs before ICU
admission. Finally, the duration of need for steroid replace-
ment may be variable and is as yet undefined.
It would therefore seem reasonable for ICU physicians to
follow the advice of Annane and avoid the use of etomidate
[12]. This ‘solution’ is only partial, as many critically ill patients
are intubated by other practitioners [13]. This poses two
problems. The first is that clinical and intensive care
physicians need to be aware that other colleagues may have
employed etomidate prior to care in the ICU. These patients
must be actively identified and given appropriate cortico-
steroid supplementation [10,13]. The second problem is
educational, in that we need to inform anaesthetic and
Emergency Department colleagues regarding current
evidence in the critical care literature.
There are also implications for clinical researchers. Firstly, the
risks of etomidate in patient groups other than those with
septic shock need to be more clearly defined. Are patients
with severe sepsis or sepsis also at risk from pharmacological
adrenalectomy? And what of critically ill patients with
nonseptic conditions such as cardiogenic shock? Secondly,
some studies of adrenal function have either not highlighted
etomidate as an issue or have been insufficiently rigorous in
dealing with etomidate as a confounding factor [2,5,13,14].
This in part might explain the wide variation of incidence of
adrenal insufficiency (0–95%) quoted for high-risk critically ill
patients [15].
In summary, pharmacological adrenalectomy does not seem
intuitively beneficial to critically ill patients. Current evidence
strongly suggests that this has a detrimental impact on
survival for patients with septic shock. Although the evidence
is less strong for other critically ill patient groups, perhaps it is
time to call a moratorium on etomidate’s use outside of
clinical research in these at-risk groups until its utility and
safety is assured. For investigations into adrenal function in
various disease states, etomidate should be avoided because
of its confounding effects. To do otherwise constitutes
inadequate research design, contributing to poor clinical
science and to continued uncertainty as regards best clinical
practice.
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